Literature DB >> 16671191

New treatment for myelodysplastic syndrome.

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16671191

Source DB:  PubMed          Journal:  FDA Consum        ISSN： 0362-1332


× No keyword cloud information.
  1 in total

1.  IMiDs mobilize acute myeloid leukemia blasts to peripheral blood through downregulation of CXCR4 but fail to potentiate AraC/Idarubicin activity in preclinical models of non del5q/5q- AML.

Authors:  Belen Lopez-Millan; Rafael Diaz de la Guardia; Heleia Roca-Ho; Eduardo Anguita; Abul B M M K Islam; Damia Romero-Moya; Cristina Prieto; Francisco Gutierrez-Agüera; Jose Antonio Bejarano-Garcia; Jose Antonio Perez-Simon; Paula Costales; Montse Rovira; Pedro Marín; Silvia Menendez; Mar Iglesias; Jose Luis Fuster; Alvaro Urbano-Ispizua; Fernando Anjos-Afonso; Clara Bueno; Pablo Menendez
Journal:  Oncoimmunology       Date:  2018-07-26       Impact factor: 8.110
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.